Skip to main content
main-content

The independent medical news service

17-12-2019 | Oncology | News | Article

TAPPS shows no difference in outcomes by talc delivery method

Individuals with malignant pleural effusion undergoing talc pleurodesis have comparable outcomes regardless of how the talc is delivered, shows a phase 3 trial reported in JAMA.

14-12-2019 | Breast cancer | Video

SABCS 2019 | Residual cancer burden after neoadjuvant therapy predicts breast cancer relapse risk

W Fraser Symmans takes us through their patient-level pooled analysis identifying residual cancer burden as a predictive factor for recurrence across all breast cancer subtypes, and its subsequent potential to inform treatment choice (6:49).

14-12-2019 | Breast cancer | Video

SABCS 2019 | Neoadjuvant ribociclib plus letrozole promising in high-risk luminal B breast cancer

Joaquín Gavilá highlights the phase 2 SOLTI-1402/CORALLEEN trial findings demonstrating comparable clinical benefit and reduced toxicity of combined neoadjuvant endocrine and CDK 4/6 inhibitor therapy versus chemotherapy in patients with high-risk luminal B breast cancer (2:44).

14-12-2019 | Breast cancer | Video

SABCS 2019 | Further support for accelerated partial breast irradiation for controlling low-risk breast cancer

Icro Meattini shares long-term findings from their phase 3 trial pitting accelerated partial breast against whole breast irradiation in women with early-stage breast cancer (1:39).

14-12-2019 | Breast cancer | Video

SABCS 2019 | Oral paclitaxel offers an option beyond IV treatment in metastatic breast cancer

Gerardo Umanzor discusses phase 3 findings showing improved survival and reduced neuropathy with orally administered versus intravenous paclitaxel in patients with metastatic breast cancer (3:12).

13-12-2019 | Breast cancer | Video

SABCS 2019 | Menopausal hormone therapy and breast cancer risk

Rowan Chlebowski outlines the findings from the Women's Health Initiative trials investigating the effect of oestrogen, either alone or with progestin, on breast cancer risk, and puts them in context of recent opposing data (4:10).

Image Credits